Dual mechanism of the OXA-23 carbapenemase inhibition by the carbapenem NA-1-157
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00918-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Marta Toth und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA. Hauptthemen laut MEDLINE: beta-Lactamases, Acinetobacter baumannii, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Carbapenem-resistant Acinetobacter baumannii continues to be a leading cause of life-threatening infections that result in high mortality rates. The major cause of carbapenem resistance in this pathogen is the production of class D carbapenemases, enzymes that inactivate the last resort carbapenem antibiotics, thus significantly diminishing the available therapeutic options. In this study, we evaluated the interaction of OXA-23, the most widely disseminated class D carbapenemase in A. baumannii clinical isolates, with the atypically modified carbapenem, NA-1-157. The MICs of this compound against strains producing OXA-23 were reduced from highly resistant levels observed for the commercial carbapenems meropenem and imipenem (16–128 µg/mL) to sensitive or intermediate levels (2–4 µg/mL). Kinetic studies showed that NA-1-157 inhibits the enzyme due to a significant decrease (>2,000-fold) in the deacylation rate relative to its closest structural analog, meropenem. Structural studies and molecular dynamics simulations demonstrated that inhibition is caused by both the inability of a water molecule to get close enough to the scissile bond to perform deacylation and by partial decarboxylation of the catalytic lysine residue upon formation of the acyl-enzyme intermediate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
- Department of Chemistry, Southern Methodist University, Dallas, Texas, USA.
- Stanford Synchrotron Radiation Lightsource, Stanford University, Menlo Park, California, USA.
- Department of Chemistry, Stanford University, Stanford, California, USA.
ORCID-Profile: Marta Toth, Nichole K Stewart, John D Buynak, Clyde A Smith, Sergei B Vakulenko
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NIGMS NIH HHS
- U.S. Department of Energy
- National Institute of General Medical Sciences
Zitieren
APA
Toth, M., Stewart, N. K., Quan, P., Khan, M. M. K., Cox, J., Buynak, J. D., Smith, C. A., & Vakulenko, S. B. (2025). Dual mechanism of the OXA-23 carbapenemase inhibition by the carbapenem NA-1-157. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00918-25
Vancouver
Toth M, Stewart NK, Quan P, Khan MMK, Cox J, Buynak JD, et al. Dual mechanism of the OXA-23 carbapenemase inhibition by the carbapenem NA-1-157. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00918-25
BibTeX
@article{Toth2025,
author = {Toth, Marta and Stewart, Nichole K and Quan, Pojun and Khan, Md Mahbub Kabir and Cox, Jonathan and Buynak, John D and Smith, Clyde A and Vakulenko, Sergei B},
title = {Dual mechanism of the OXA-23 carbapenemase inhibition by the carbapenem NA-1-157},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00918-25}
}
EUVIMED